Matches in Nanopublications for { ?s <http://www.w3.org/2000/01/rdf-schema#label> ?o ?g. }
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "hyperglycemia , an adverse effect that physicians should bear in mind , when caring for patients with diabetes mellitus ( DM ) and coronavirus disease 2019 ( COVID)-19 ) caused by the severe acute respiratory syndrome coronavirus 2 ( SARS)-CoV-2 )" provenance.
- OBJECT label "by other viruses" provenance.
- OBJECT label "by other viruses" provenance.
- OBJECT label "by other viruses" provenance.
- OBJECT label "by other viruses" provenance.
- OBJECT label "by other viruses" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label "the risk of any severe AEs by 52 % ( 0.48 , 0.34–0.67 ) , 24 % ( 0.77 , 0.63–0.92 ) , 40 % ( 0.60 , 0.37–0.98 ) , and 50 % ( 0.50 , 0.25–0.98 ) respectively" provenance.
- OBJECT label ""death rate in certain patients subgroups ( positive results )"" provenance.
- OBJECT label ""death rate in certain patients subgroups ( positive results )"" provenance.
- OBJECT label ""death rate in certain patients subgroups ( positive results )"" provenance.
- OBJECT label ""death rate in certain patients subgroups ( positive results )"" provenance.
- OBJECT label ""death rate in certain patients subgroups ( positive results )"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label ""stronger affinity to dexamethasone ( Dex ) s theoretical ( glucocorticoid ) receptor with a superior docking score of −14.7 and a good binding energy value of −147.48 kcal / mol"" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "the incidence of PONV ( 3.05 % , 22/721 )" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "better 28-day survival in severe COVID-19 patients requiring ventilation or oxygen" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "with usual care or placebo ( 3 trials , 1282 patients , and 527 deaths )" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "reduce mortality in COVID-19 patients in hospital" provenance.
- OBJECT label "transactivation of nuclear factor ( NF)-κ Bwithout inhibiting translocation of the nuclear factor ( NF)-κ B p65 subunit to the nucleus" provenance.
- OBJECT label "transactivation of nuclear factor ( NF)-κ Bwithout inhibiting translocation of the nuclear factor ( NF)-κ B p65 subunit to the nucleus" provenance.